Pro-Pointer, Inc. (PINKSHEETS: PPII), through its wholly owned subsidiary Coenzyme-A Technologies, Inc., has announced its latest proprietary development, the Coenzyme-A(TM) "MODULATOR MATRIX V," a proprietary nutraceutical formula that especially addresses the symptoms of Perimenopausal and menopausal women. Research shows that hormonal changes and chemical imbalances in perimenopausal and menopausal women contribute to higher levels of cholesterol, increased fat storage, stress, acne, anxiety, lack of energy, and depression.
Cardiovascular diseases are the main cause of death in men and women. For women their incidence rapidly increases during the Perimenopausal and Menopausal periods, which is directly related to increased levels of cholesterol and triglycerides.
The human body has a natural tendency to store away any excess calorie intake in its fat depot; this natural tendency increases in Perimenopausal and Menopausal women. Coenzyme-A is the key that unlocks this fat depot and is the agent that converts the stored fat into energy through lipid metabolism, which reduces cholesterol and triglycerides by increasing fat utilization.
Current studies also show that the metabolic enzyme (Coenzyme-A) plays a major role in the body's ability to cope with stress, anxiety, and depression and further strengthen the immune system. In combating stress and anxiety, the body secretes hormones as a means to adapt to the ever-increasing stress levels. These hormones are derivatives of cholesterol and an increased demand for them by the human body will prioritize and draw on the remaining available Coenzyme-A pool.
The world nutraceutical market, which is expected to top $15 billion this year, has enjoyed double-digit growth over the last few years and is expected to continue. Growth is believed to be driven by new product introduction and health consciousness within the aging population. The U.S. female baby boomers which are expected to reach well over 50 million by 2012 drive the U.S. market in the sense that they are the generation, which is most likely to demand control over the course of their medical care and well-being.
Coenzyme-A Technologies, Inc. plans to penetrate this market through new and innovative nutraceutical developments. Promoting them within their existing distribution channels as well as the implementation of magazine advertising and an aggressive worldwide internet marketing campaign.
Given the above statistics and the ever rising demand for products that can naturally address and effectively correct the symptoms of Perimenopausal and Menopausal conditions, this Coenzyme-A development represents a market value well exceeding $5 million in annual revenues.
ABOUT COENZYME-A TECHNOLOGIES, INC. -- Coenzyme-A Technologies, Inc. is an innovative company that has applied new technology to the formulation and manufacture of a series of proprietary products which address nutritional deficiencies that result from the stress of modern day living, chemical imbalances within the body, and the effects of aging. Coenzyme-A is the first nutraceutical product to combine nutritional components that can be successfully used by the body to support its manufacture and utilization of cellular Coenzyme-A (The Master Coenzyme). Coenzyme-A contains a specific set of substrates that are designed to assist the body in converting fats, carbohydrates and proteins into energy at the cellular level. See Company website -- www.coenzyme-a.com.